View Cart  

Genzyme Presents Second Phase III Study of Once-daily Oral Aubagio

A A
Genzyme announced that key data from the TOWER trial were presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
Yahoo! Finanace